258 related articles for article (PubMed ID: 32078124)
1. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
Xu XS; Moreau P; Usmani SZ; Lonial S; Jakubowiak A; Oriol A; Krishnan A; Bladé J; Luo M; Sun YN; Zhou H; Nnane I; Deraedt W; Qi M; Ukropec J; Clemens PL
Adv Ther; 2020 Apr; 37(4):1464-1478. PubMed ID: 32078124
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
Xu XS; Dimopoulos MA; Sonneveld P; Ho PJ; Belch A; Leiba M; Capra M; Gomez D; Medvedova E; Iida S; Min CK; Schecter J; Jansson R; Zhang L; Sun YN; Clemens PL
Adv Ther; 2018 Nov; 35(11):1859-1872. PubMed ID: 30374808
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Dimopoulos M; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Yang H; Klippel Z; Zahlten-Kumeli A; Usmani SZ
Lancet; 2020 Jul; 396(10245):186-197. PubMed ID: 32682484
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Jakubowiak A; Usmani SZ; Krishnan A; Lonial S; Comenzo RL; Wang J; de Boer C; Deraedt W; Weiss BM; Schecter JM; Chari A
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):701-710. PubMed ID: 34274290
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab.
Kim K; Phelps MA
Clin Pharmacokinet; 2023 Jun; 62(6):789-806. PubMed ID: 37129750
[TBL] [Abstract][Full Text] [Related]
8. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Plesner T; Arkenau HT; Gimsing P; Krejcik J; Lemech C; Minnema MC; Lassen U; Laubach JP; Palumbo A; Lisby S; Basse L; Wang J; Sasser AK; Guckert ME; de Boer C; Khokhar NZ; Yeh H; Clemens PL; Ahmadi T; Lokhorst HM; Richardson PG
Blood; 2016 Oct; 128(14):1821-1828. PubMed ID: 27531679
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study.
Takamatsu H; Iida S; Shibayama H; Shibayama K; Yamazaki H; Suzuki K
Int J Hematol; 2020 May; 111(5):692-701. PubMed ID: 32002821
[TBL] [Abstract][Full Text] [Related]
10. Daratumumab Split First Versus Single Dosing Schedule Among Patients With Multiple Myeloma Treated in a US Community Oncology Setting: A Retrospective Observational Study.
Rifkin R; Singer D; Aguilar KM; Baidoo B; Maiese EM
Clin Ther; 2019 May; 41(5):866-881.e7. PubMed ID: 31030993
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma.
Richard S; Jagannath S; Cho HJ; Parekh S; Madduri D; Richter J; Chari A
Expert Rev Hematol; 2021 Jan; 14(1):31-45. PubMed ID: 33331794
[No Abstract] [Full Text] [Related]
12. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Chari A; Rodriguez-Otero P; McCarthy H; Suzuki K; Hungria V; Sureda Balari A; Perrot A; Hulin C; Magen H; Iida S; Maisnar V; Karlin L; Pour L; Parasrampuria DA; Masterson T; Kosh M; Yang S; Delioukina M; Qi M; Carson R; Touzeau C
Br J Haematol; 2021 Mar; 192(5):869-878. PubMed ID: 33216361
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma.
Dosne AG; Li X; Luo MM; Nnane I; Dimopoulos MA; Terpos E; Sonneveld P; Kampfenkel T; Carson R; Amin H; Perez Ruixo J; Zhou H; Sun YN; Xu Y
Br J Clin Pharmacol; 2023 May; 89(5):1640-1655. PubMed ID: 36484341
[TBL] [Abstract][Full Text] [Related]
14. Successful use of split-dose intravenous daratumumab in a multiple myeloma patient after a first-dose life-threatening infusion-related reaction.
Aykaş F; Karakuş V; Sevindik ÖG
J Oncol Pharm Pract; 2024 Mar; 30(2):397-399. PubMed ID: 37990526
[TBL] [Abstract][Full Text] [Related]
15. Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients.
Luo MM; Usmani SZ; Mateos MV; Nahi H; Chari A; San-Miguel J; Touzeau C; Suzuki K; Kaiser M; Carson R; Heuck C; Qi M; Zhou H; Sun YN; Parasrampuria DA
J Clin Pharmacol; 2021 May; 61(5):614-627. PubMed ID: 33145788
[TBL] [Abstract][Full Text] [Related]
16. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
18. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
Berenson JR; Cartmell A; Bessudo A; Lyons RM; Harb W; Tzachanis D; Agajanian R; Boccia R; Coleman M; Moss RA; Rifkin RM; Patel P; Dixon S; Ou Y; Anderl J; Aggarwal S; Berdeja JG
Blood; 2016 Jun; 127(26):3360-8. PubMed ID: 27207788
[TBL] [Abstract][Full Text] [Related]
19. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ
Lancet Haematol; 2020 May; 7(5):e370-e380. PubMed ID: 32213342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
